ArticleFrontiers in oncology2026
A preliminary study to evaluate efficacy and safety of Lugol's solution following radioiodine for remnant ablation in differentiated thyroid cancer.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: This randomized controlled trial aimed to determine if Lugol's solution following radioactive iodine (RAI) therapy enhances the efficacy of ablation and mitigates radiation-induced toxicity in patients with differentiated thyroid cancer. Methods: In this prospective study, 97 patients were enrolled and randomized to control group (RAI) and test group (RAI + Lugol's solution). The primary endpoint was the rate of successful ablation. The secondary endpoint was short-term (d3 and d10) and long-term (6- to 9-month after RAI therapy) adverse events (AEs). Results: The rate of negative DxWBS was similar between control and test group (93.3% vs. 91.2%, Conclusion: In this preliminary study, the addition of Lugol's Solution following RAI showed non-inferior ablation efficacy with a numerically lower incidence of long-term AEs, despite numerically higher short-term AE rates. Clinical trial information: It was registered at Chinese Clinical Trial Registry with identifier ChiCTR1900027705 at November 24
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.